NCM’s strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribution network in New York State. The American market for molecular imaging agents currently exceeds $1.3 billion annually and is expected to grow to over $3 billion by 2020.

Anwer Rizvi,
President & CEO, has a proven track record of developing a distribution network for PET in the United States, Europe and Asia. Due to his efforts at IBA, he in-licensed several compounds for IBA’s network, totaling a combined value of $500+ million. Mr. Rizvi was the founder and president of IBA Molecular from 2001-2009. Continue>>


Tour our up and coming state-of-the-art manufacturing facility



.
The radionuclides employed for imaging purposes are isotopes of radioactive elements such as uranium or iodine that produce gamma rays with high penetrating power that can be recorded by a gamma camera or scintillation detector that captures the images..>

View a quick presentation of the science behind radio-pharmaceuticals.
NCM USA LLC
461 Park Avenue South
New York, NY 10016

Office:  212-719-2322
Fax: (212) 997-4119


Email: info@ncm-usa.com



© NCM USA LLC 2011 All Rights Reserved Home Contact us Investor Relations